Former Genentech CEO Levinson joins Amyris' board

> AVI BioPharma's board has appointed CFO J. David Boyle II as interim president and CEO. The appointment follows former CEO and director Leslie Hudson's resignation. The board plans to initiate a search for CEO candidates, which will include both external and internal candidates. AVI release

> Amyris Biotechnologies announced that former Genentech CEO Arthur Levinson, Ph.D, is joining the company's board of directors. Amyris release

> Sigma Pharmaceuticals says CEO and Managing Director Elmo De Alwis has resigned both positions. He will continue in the role until the board has identified and appointed his replacement. Sigma release

> Sangamo BioSciences has appointed William Ringo as chairman of the company's board of directors effective April 16, 2010. Sangamo release

> Shareholders of Cumberland Pharmaceuticals have elected Gordon R. Bernard, M.D., Jonathan Griggs, and James Jones as new members of the company's board of directors at its annual meeting. Directors A.J. Kazimi and Martin E. Cearnal were also re-elected. Cumberland release

> Richard Ranieri has joined Dendreon as senior vice president of human resources, effective April 19, 2010. Dendreon release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.